• AVITA Medical Receives U.S. FDA Investigational Device Exemption Approval biospectrumasia
    September 18, 2019
    The pivotal studies leading to the RECELL System’s FDA premarket approval (PMA) for the treatment of acute thermal burns demonstrated that the RECELL System treated burns using 97.5 percent less donor skin when used alone in second-degree burns, and 32 pe
  • Avita Medical to commercialize wounds treatment device in Japan biospectrumasia
    March 08, 2019
    Australia based AVITA Medical, regenerative medicine company, announced that it has collaborated with COSMOTEC, an M3 Group company, to market and distribute the RECELL® Autologous Cell Harvesting Device (RECELL® System) for the treatment of burns and oth
  • Avita Medical to commercialize wounds treatment device in Japan biospectrumasia
    March 06, 2019
    Australia based AVITA Medical, regenerative medicine company, announced that it has collaborated with COSMOTEC, an M3 Group company, to market and distribute the RECELL® Autologous Cell Harvesting Device (RECELL® System) for the treatment of burns and oth
PharmaSources Customer Service